Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma: Updated Results

Beata Holkova, MD, Maciej Kmieciak, PhD, Prithviraj Bose, MD, Shuo Ma, MD PhD, Amy Kimball, MD PhD, Mary Beth Tombes, RN, Ellen Shrader, BS, Wen Wan, PhD, Caryn Weir-Wiggins, Elizabeth Stoddert, Amanda Garnett Singh, RN, BSN, April Dean, BS, Sarah Conine, PhD, Heidi Sankala, PhD, John D. Roberts, MD, Thomas C. Shea, MD, Steven Grant, MD

Blood (2014) 124 (21): 3050.

https://doi.org/10.1182/blood.V124.21.3050.3050

Published: 2014

Journal Articles

Phase I Trial Of Carfilzomib In Combination With Vorinostat (SAHA) In Patients With Relapsed/Refractory B-Cell Lymphomas

Beata Holkova, MD, Maciej Kmieciak, PhD, Prithviraj Bose, MD, Paul M. Barr, MD, Mary Beth Tombes, RN, Ellen Shrader, BS, Erin Cebula, MPH, CCRP, Emily Pierce, RN, CCRC, Megan M. Herr, BS, Heidi Sankala, PhD, Changyong Feng, PhD, Richard I Fisher, MD, Steven Grant, MD, Jonathan W. Friedberg, MD

Blood (2013) 122 (21): 4375.

https://doi.org/10.1182/blood.V122.21.4375.4375

Published: 2013

Journal Articles

Phase I Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, or Peripheral T-Cell Lymphoma

Beata Holkova, MD, Thomas C. Shea, MD, Prithviraj Bose, MD, Mary Beth Tombes, RN, Ellen Shrader, Wen Wan, PhD, Caryn Weir-Wiggins, Elizabeth Stoddert, Heidi Sankala, PhD, Maciej Kmieciak, PhD, John D. Roberts, MD, Steven Grant, MD

Blood (2012) 120 (21): 1794.

https://doi.org/10.1182/blood.V120.21.1794.1794

Published: 2012

Journal Articles

Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis - One Year Update

Beata Holkova, MD, Prithviraj Bose, MD, Mary Beth Tombes, RN, Ellen Shrader, Wen Wan, PhD, Caryn Weir-Wiggins, Elizabeth Stoddert, Heidi Sankala, PhD, Maciej Kmieciak, PhD, John D. Roberts, MD, Guillermo Garcia-Manero, MD, Steven Grant, MD

Blood (2012) 120 (21): 3588.

https://doi.org/10.1182/blood.V120.21.3588.3588

Published: 2012

Journal Articles

Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms - Update of the “Bolus” Infusion Schedule of Alvocidib.

Beata Holkova, MD, Edward B. Perkins, MD, PhD, Prithviraj Bose, MD, Daniel M Sullivan, MD, Rachid Baz, MD, Mary Beth Tombes, RN, Ellen Shrader, Viswanathan Ramakrishnan, PhD, Wen Wan, PhD, Heidi Sankala, PhD, Maciej Kmieciak, PhD, John D. Roberts, MD, Steven Grant, MD

Blood (2012) 120 (21): 2959.

https://doi.org/10.1182/blood.V120.21.2959.2959

Published: 2012

Journal Articles

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

Beata Holkova, MD, Edward B. Perkins, MD, PhD, Lubomir Sokol, MD, PhD, Kristy L. Richards, PhD, MD, Samir Parekh, MD, Rebecca Elstrom, MD, Ashraf Z. Badros, MD, Igor Espinoza-Delgado, MD, Michael J. Schell, PhD, Amy Kimball, MD, PhD, Mary Beth Tombes, RN, Ellen Shrader, Heidi Sankala, PhD, Domenico Coppola, MD, Maciej Kmieciak, PhD, Daniel Sullivan, MD, John D. Roberts, MD, Steven Grant, MD

Blood (2011) 118 (21): 779.

https://doi.org/10.1182/blood.V118.21.779.779

Published: 2011

Journal Articles

A Phase II Study of the MEK 1/2 Inhibitor AZD6244 (Selumetinib, ARRY-142866) in Relapsed or Refractory Multiple Myeloma

Beata Holkova, MD, Ashraf Z. Badros, MD, Robert Geller, MD, Peter M. Voorhees, MD, Adriana Zingone, MD, PhD, Neha Korde, MD, Hui-Yi Lin, PhD, Mary Beth Tombes, RN, Ellen Shrader, Heidi Sankala, PhD, Maciej Kmieciak, PhD, John D. Roberts, MD, Daniel Sullivan, MD, Ola Landgren, MD, PhD, Steven Grant, MD

Blood (2011) 118 (21): 2931.

https://doi.org/10.1182/blood.V118.21.2931.2931

Published: 2011

Journal Articles

Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis

Beata Holkova, MD, Mary Beth Tombes, RN, Ellen Shrader, Sheryl S. Cooke, RN, Wen Wan, PhD, Heidi Sankala, PhD, Maciej Kmieciak, PhD, John D. Roberts, MD, Guillermo Garcia-Manero, Steven Grant, MD

Blood (2011) 118 (21): 2598.

https://doi.org/10.1182/blood.V118.21.2598.2598

Published: 2011

NARROW

Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma: Updated Results

Phase I Trial Of Carfilzomib In Combination With Vorinostat (SAHA) In Patients With Relapsed/Refractory B-Cell Lymphomas

Phase I Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, or Peripheral T-Cell Lymphoma

Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis - One Year Update

Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms - Update of the “Bolus” Infusion Schedule of Alvocidib.

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

A Phase II Study of the MEK 1/2 Inhibitor AZD6244 (Selumetinib, ARRY-142866) in Relapsed or Refractory Multiple Myeloma

Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only